Over the past 10 years the HIV vaccine field has worked to define the roadblocks preventing the development of an HIV vaccine and has worked to develop strategies to overcome them. Recent success in isolation of potent broadly neutralizing antibodies (bnAbs), in discovery of pathways and mechanisms of bnAb induction, in defining novel modes of bnAb regulation and in discovery of atypical mechanisms of CD8 T cell killing of HIV-infected CD4+ T cells have opened new avenues for strategies for HIV vaccine design. Work now is ongoing to move new vaccine concepts into proof-of-concept experimental medicine phase I clinical trials, and to test the effect of new immunization strategies on the human immune system. In addition, efforts are also ongoing to improve the design of the pox prime/pox + Env boost strategy that resulted in an estimated 31% efficacy in the RV144 trial. Progress made to date in overcoming vaccine roadblocks will be discussed, and the remaining path forward for HIV vaccine development will be outlined.
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.